国际产前诊断学会2022年辩论3:是否应向所有孕妇提供胎儿基因组测序
本文总结第26届国际产前诊断与治疗会议上关于是否应向所有孕妇提供胎儿基因组测序的辩论。双方专家分别权衡了无产前表型即可诊断严重儿童疾病并早期治疗的优点,以及变异分类困难、咨询复杂、医疗成本和家庭负担等缺点,一致认为需更多研究探索其临床效用与伦理问题。
要点
- 产前三联外显子组测序已整合到胎儿结构异常孕妇的诊疗中。
- 辩论双方认为全基因组测序用于所有孕妇的利弊尚需权衡。
- 双方一致认为需更多研究探索全基因组测序的临床效用与伦理问题。
核心结论
- 辩论双方虽对利弊权衡不同,但一致认为需更多研究进一步探索对所有孕妇进行基因组测序的临床效用和伦理问题。
研究设计与样本
- 本文为第26届国际产前诊断与治疗会议上关于是否应向所有孕妇提供胎儿基因组测序的辩论总结。
主要发现
- 产前三联外显子组测序已整合到胎儿结构异常孕妇的诊疗中。
- 优点包括无产前可观察表型即可诊断严重儿童疾病,从而有早期治疗的可能。
- 缺点包括变异分类困难、咨询复杂、医疗成本以及医疗系统和家庭负担,尤其是发现成人发病疾病或意义不明变异时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prenatal trio exome sequencing (ES) has become integrated into the care for pregnant women when the fetus has structural anomalies. Details regarding optimizing indications for prenatal exome sequencing, its detection rates with different categories of fetal anomalies, and principles of interpretation of pathogenicity of sequence variants are still under investigation. However, there is now growing consensus about its benefits for finding the cause of fetal structural anomalies. What is not established, is whether exome or genome sequencing (GS) has a place in the care of all pregnant women. This report is a summary of the debate on this topic at the 26th International Conference on Prenatal Diagnosis and Therapy. Both expert debaters considered the advantages and disadvantages. Advantages include the ability to diagnose serious childhood conditions without a prenatally observable phenotype, which creates the potential of early treatments. Disadvantages include difficulties with variant classification, counseling complexities, healthcare cost, and the burden on healthcare systems and families, in particular with the discovery of adult-onset disorders or variants of uncertain significance. Although both debaters weighed the balance of these conflicting arguments differently, they agreed that more research is needed to further explore the clinical utility and ethical aspects of GS for all pregnant women.
引用
- Van den Veyver IB, Yaron Y, Deans ZC, et al. International Society for Prenatal Diagnosis 2022 debate 3-Fetal genome sequencing should be offered to all pregnant patients. Prenat Diagn. 2022. PMID: 36221164. doi:10.1002/pd.6247
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。